For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.

Source Reference: Fizazi K, et al "Final overall survival with talazoparib plus enzalutamide as initial treatment in patients with homologous recombination repair-deficient mCRPC in the phase 3 ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

2 mCRPC is a cancer that has spread beyond the prostate gland ... In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...